201 related articles for article (PubMed ID: 15627029)
21. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
Lonergan JT; McComsey GA; Fisher RL; Shalit P; File TM; Ward DJ; Williams VC; Hessenthaler SM; Lindsey L; Hernandez JE;
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):935-42. PubMed ID: 15220700
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
23. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.
Moyle GJ; Baldwin C; Langroudi B; Mandalia S; Gazzard BG
J Acquir Immune Defic Syndr; 2003 May; 33(1):22-8. PubMed ID: 12792351
[TBL] [Abstract][Full Text] [Related]
24. Lipoatrophy and mitochondrial DNA assays: see all, know all?
Brinkman K
AIDS; 2005 Jan; 19(1):91-2. PubMed ID: 15627038
[No Abstract] [Full Text] [Related]
25. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Tebas P; Zhang J; Hafner R; Tashima K; Shevitz A; Yarasheski K; Berzins B; Owens S; Forand J; Evans S; Murphy R
J Antimicrob Chemother; 2009 May; 63(5):998-1005. PubMed ID: 19299471
[TBL] [Abstract][Full Text] [Related]
26. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors.
Stankov MV; Lücke T; Das AM; Schmidt RE; Behrens GM;
Antivir Ther; 2007; 12(2):205-16. PubMed ID: 17503663
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
28. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
Boyd MA; Carr A; Ruxrungtham K; Srasuebkul P; Bien D; Law M; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange JM; Phanuphak P; Cooper DA; Reiss P
J Infect Dis; 2006 Sep; 194(5):642-50. PubMed ID: 16897663
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.
Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P
HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930
[TBL] [Abstract][Full Text] [Related]
30. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting.
Maisonneuve C; Igoudjil A; Begriche K; Lettéron P; Guimont MC; Bastin J; Laigneau JP; Pessayre D; Fromenty B
Antivir Ther; 2004 Oct; 9(5):801-10. PubMed ID: 15535418
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Gerschenson M; Kim C; Berzins B; Taiwo B; Libutti DE; Choi J; Chen D; Weinstein J; Shore J; da Silva B; Belsey E; McComsey GA; Murphy RL
J Antimicrob Chemother; 2009 Jun; 63(6):1244-50. PubMed ID: 19321503
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
[TBL] [Abstract][Full Text] [Related]
33. [Association between the change regularity of peripheral blood mononuclear cell mitochondrial deoxyribonucleic acid content and human immunodeficiency virus-related lipodystrophy].
Wu P; Gu WB; Zhang L; Li YL; Qiu ZF; Han Y; Xie J; Li TS
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(21):1448-52. PubMed ID: 21914278
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial DNA content of peripheral blood mononuclear cells in ART untreated & stavudine/zidovudine treated HIV-1-infected patients.
Subashini D; Dinesha TR; Srirama RB; Boobalan J; Poongulali S; Chitra DA; Mothi SN; Solomon SS; Saravanan S; Solomon S; Balakrishnan P
Indian J Med Res; 2018 Aug; 148(2):207-214. PubMed ID: 30381544
[TBL] [Abstract][Full Text] [Related]
36. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
Hulgan T; Haubrich R; Riddler SA; Tebas P; Ritchie MD; McComsey GA; Haas DW; Canter JA
AIDS; 2011 Jan; 25(1):37-47. PubMed ID: 20871389
[TBL] [Abstract][Full Text] [Related]
37. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
Chêne G; Amellal B; Pédrono G; Gourlain K; Rancinan C; Journot V; Cotte L; Palmer P; Castro ND; Calvez V; Molina JM;
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):54-61. PubMed ID: 17263633
[TBL] [Abstract][Full Text] [Related]
38. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
39. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
Hammond E; McKinnon E; Nolan D
Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
